CA2602088C - Biomarkers for ovarian cancer and endometrial cancer - Google Patents

Biomarkers for ovarian cancer and endometrial cancer Download PDF

Info

Publication number
CA2602088C
CA2602088C CA2602088A CA2602088A CA2602088C CA 2602088 C CA2602088 C CA 2602088C CA 2602088 A CA2602088 A CA 2602088A CA 2602088 A CA2602088 A CA 2602088A CA 2602088 C CA2602088 C CA 2602088C
Authority
CA
Canada
Prior art keywords
biomarkers
cancer
endometrial
ovarian cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2602088A
Other languages
English (en)
French (fr)
Other versions
CA2602088A1 (en
Inventor
Eric Thomas Fung
Robert Bast
Daniel W. Chan
Jin Song
Vladimir Podust
Zhen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Texas System
Aspira Womens Health Inc
Original Assignee
Johns Hopkins University
University of Texas System
Aspira Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, University of Texas System, Aspira Womens Health Inc filed Critical Johns Hopkins University
Publication of CA2602088A1 publication Critical patent/CA2602088A1/en
Application granted granted Critical
Publication of CA2602088C publication Critical patent/CA2602088C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Agronomy & Crop Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2602088A 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer Active CA2602088C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66209005P 2005-03-11 2005-03-11
US60/662,090 2005-03-11
PCT/US2006/008578 WO2006099126A2 (en) 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer: hepcidin

Publications (2)

Publication Number Publication Date
CA2602088A1 CA2602088A1 (en) 2006-09-21
CA2602088C true CA2602088C (en) 2021-07-27

Family

ID=36992262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602088A Active CA2602088C (en) 2005-03-11 2006-03-10 Biomarkers for ovarian cancer and endometrial cancer

Country Status (11)

Country Link
US (2) US7510842B2 (enExample)
EP (1) EP1869462B1 (enExample)
JP (1) JP5069214B2 (enExample)
KR (1) KR101310000B1 (enExample)
CN (1) CN101189516A (enExample)
AU (1) AU2006223374B2 (enExample)
CA (1) CA2602088C (enExample)
IL (1) IL185496A (enExample)
MX (1) MX2007011024A (enExample)
NZ (1) NZ560976A (enExample)
WO (1) WO2006099126A2 (enExample)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533998B2 (en) 2008-07-18 2020-01-14 Bio-Rad Laboratories, Inc. Enzyme quantification
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
WO2012047930A2 (en) 2010-10-04 2012-04-12 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
DK2199801T3 (da) * 2004-07-14 2013-08-05 Univ California Biomarkører til tidlig påvisning af ovariecancer
US9488655B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP4801930B2 (ja) * 2005-05-02 2011-10-26 株式会社Ｍｃｂｉ 新規肝がんバイオマーカーおよび該バイオマーカーを用いた肝がんの検出方法
DE602006008310D1 (de) * 2005-06-22 2009-09-17 Univ Johns Hopkins Biomarker für eierstockkrebs: mit ctap3 verwandte proteine
US8465929B2 (en) * 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer
US7672916B2 (en) * 2005-08-16 2010-03-02 The Trustees Of Columbia University In The City Of New York Methods, systems, and media for music classification
US7972770B2 (en) * 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
EP3913375A1 (en) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
EP2021113A2 (en) 2006-05-11 2009-02-11 Raindance Technologies, Inc. Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
AU2007275638B2 (en) * 2006-07-21 2014-01-16 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
JPWO2008047485A1 (ja) * 2006-10-17 2010-02-18 直久 友杉 活性型ヘプシジンを指標とした、鉄代謝異常の診断方法
WO2008049175A1 (en) * 2006-10-24 2008-05-02 Katholieke Universiteit Leuven High discriminating power biomarker diagnosing
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
PE20090722A1 (es) * 2007-02-02 2009-07-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008123948A1 (en) * 2007-03-27 2008-10-16 Vermillion, Inc. Biomarkers for ovarian cancer
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
JPWO2008146903A1 (ja) 2007-05-31 2010-08-19 直久 友杉 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
EP2637020A3 (en) 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
CA2694112A1 (en) * 2007-07-20 2009-01-29 The University Of Utah Research Foundation Identification and quantification of biomarkers for evaluating the risk of preterm birth
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
WO2009058331A2 (en) * 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
AR069062A1 (es) 2007-11-02 2009-12-23 Lilly Co Eli Anticuerpo anti-hepcidina
EP2222345B1 (en) * 2007-11-23 2016-03-23 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
AU2009278386B2 (en) 2008-08-05 2015-05-21 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
PL2733492T3 (pl) 2008-08-05 2016-08-31 Toray Industries Sposób wykrywania nowotworów
ES2432018T3 (es) * 2008-08-06 2013-11-29 Eli Lilly And Company Anticuerpos selectivos anti-hepcidina-25 y usos de los mismos
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2273272A1 (en) 2009-07-06 2011-01-12 Stichting Katholieke Universiteit Method for predicting the outcome of chemotherapy in ovarian cancer
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
WO2011096533A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
RU2567657C2 (ru) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MX340014B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9321818B2 (en) * 2010-02-09 2016-04-26 Academia Sinica Dermcidin-derived peptides for lung cancer diagnostics
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP4484577A3 (en) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2011149942A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
US20120046185A1 (en) * 2010-08-06 2012-02-23 Vermillion, Inc. Panel of biomarkers for ovarian cancer
CN102375063A (zh) * 2010-08-23 2012-03-14 湖州赛尔迪生物医药科技有限公司 一种常见蛋白质的免疫质谱试剂盒及制备方法
EP2622103B2 (en) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwich assays in droplets
EP2630498A4 (en) * 2010-10-22 2014-10-01 Vermillion Inc PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN103717739B (zh) 2011-08-04 2015-07-29 东丽株式会社 癌的治疗和/或预防用药物组合物
EP2740798B1 (en) 2011-08-04 2016-12-07 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
CN103717238B (zh) 2011-08-04 2016-10-12 东丽株式会社 胰癌的治疗和/或预防用药物组合物
CA2844033C (en) 2011-08-04 2021-07-27 Toray Industries, Inc. Method for detecting pancreatic cancer
CN103764825B (zh) 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
CA2844042C (en) 2011-08-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2844038C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
CN104039810A (zh) 2011-08-29 2014-09-10 加利福尼亚大学董事会 使用高密度脂蛋白(hdl)相关分子治疗和预防促炎性病状
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
MX360208B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2013223147B2 (en) 2012-02-21 2017-10-05 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2818481T (pt) 2012-02-21 2019-10-25 Toray Industries Composição farmacêutica para tratamento e/ou prevenção de cancro
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
DK2968503T3 (en) * 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
TWI598577B (zh) * 2014-03-28 2017-09-11 Metallogenics Co Ltd Method for obtaining data for determining possibility of carcinogenesis of endometriotic ovarian cysts, and diagnostic apparatus thereof
EP2955517A1 (de) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Stabilisierung von Körperflüssigkeitsproben durch die Zugabe von Detergenz
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
GB2530521B (en) * 2014-09-24 2020-06-10 Map Ip Holding Ltd Mass spectral analysis of patient samples for the detection of the human chorionic gonadotropin
WO2016046558A1 (en) * 2014-09-24 2016-03-31 Map Ip Holding Limited Methods for providing a prognosis of pregnancy
IL256399B (en) 2015-06-19 2022-09-01 Sera Prognostics Inc Biomarker pairs for predicting preterm birth
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CN106872593B (zh) * 2017-02-04 2021-05-04 江西省妇幼保健院 溶血磷脂酸作为标志物在检测子宫内膜异位症中的应用
WO2019036032A1 (en) 2017-08-18 2019-02-21 Sera Prognostics, Inc PREGNANCY CLOCK PROTEINS FOR PREDICTING THE DATE AND MOMENT OF BIRTH
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2019046814A1 (en) 2017-09-01 2019-03-07 Venn Biosciences Corporation IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR THE DIAGNOSIS AND MONITORING OF TREATMENT
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
CN115997121A (zh) * 2020-02-19 2023-04-21 艾思彼拉妇女保健公司 具有改善特异性的子宫内膜异位症评估的组成物
AU2023406952A1 (en) * 2022-12-02 2025-06-19 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
WO2024192014A1 (en) * 2023-03-12 2024-09-19 Novelna Inc. Endometrial cancer detection proteins and methods of use thereof
CN119757576A (zh) * 2024-12-26 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于区分健康与宫颈癌的代谢标志物组合及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
WO2003057014A2 (en) * 2002-01-07 2003-07-17 John Hopkins University Biomarkers for detecting ovarian cancer
EP1540010B8 (en) * 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
EP1578254B1 (en) 2002-11-19 2013-03-06 DRG International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US7670792B2 (en) * 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US8465929B2 (en) * 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer

Also Published As

Publication number Publication date
CA2602088A1 (en) 2006-09-21
IL185496A0 (en) 2008-01-06
MX2007011024A (es) 2009-11-23
US7510842B2 (en) 2009-03-31
KR20080044801A (ko) 2008-05-21
US20100068724A1 (en) 2010-03-18
CN101189516A (zh) 2008-05-28
AU2006223374B2 (en) 2011-07-21
AU2006223374A1 (en) 2006-09-21
EP1869462A4 (en) 2009-01-14
JP5069214B2 (ja) 2012-11-07
EP1869462A2 (en) 2007-12-26
EP1869462B1 (en) 2013-05-08
WO2006099126A2 (en) 2006-09-21
IL185496A (en) 2012-07-31
KR101310000B1 (ko) 2013-09-25
US20070054329A1 (en) 2007-03-08
WO2006099126A3 (en) 2006-12-07
NZ560976A (en) 2011-06-30
JP2008533471A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2006074430A3 (en) Biomarkers for melanoma
WO2007002535A3 (en) Biomarkers for ovarian cancer
IL251791B (en) Ovarian cancer biomarkers: ctap3-related proteins
WO2007086904A3 (en) Compositions for use in identification of adenoviruses
WO2006089125A3 (en) Methods of detecting ovarian cancer
WO2005098446A3 (en) Biomarkers for ovarian cancer
WO2007118222A3 (en) Compositions for the use in identification of fungi
WO2007062090A8 (en) Methods and compositions related to b cell assays
CA2697508A1 (en) Method for detecting gynecologic cancer
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
WO2006034032A3 (en) Biomarkers for breast cancer
WO2010053816A3 (en) Biomarkers for diagnosis of breast cancer
WO2007051069A3 (en) Urinary proteomic biomarker patterns in preeclampsia
WO2010078333A3 (en) Benzoxazole-based fluorescent metal ion indicators
WO2007002527A3 (en) BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN
WO2007002069A3 (en) Serum biomarkers for breast cancer
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2006063133A3 (en) Biomarker for inflammatory bowel disease
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2006113289A3 (en) Saposin d and fam3c are biomarkers for alzheimer&#39;s disease
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders

Legal Events

Date Code Title Description
EEER Examination request